Current Report Filing (8-k)
August 02 2021 - 7:16AM
Edgar (US Regulatory)
0000888491
false
0000888491
2021-07-30
2021-07-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 30, 2021
OMEGA HEALTHCARE INVESTORS, INC.
(Exact name of registrant as specified in
its charter)
Maryland
|
1-11316
|
38-3041398
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
303 International Circle
Suite 200
Hunt Valley, Maryland 21030
(Address of principal executive offices
/ Zip Code)
(410) 427-1700
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act.
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Securities registered pursuant to Section
12(b) of the Securities Exchange Act of 1934:
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $.10 par value
|
OHI
|
New York Stock Exchange
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Effective July 30, 2021, the
Board of Directors of Omega Healthcare Investors, Inc. (the “Company”) appointed Dr. Lisa Egbuonu-Davis to the Board of Directors,
to serve until the Company’s 2022 annual meeting of stockholders (the “2022 Annual Meeting”) and until her successor
is elected and qualified.
Dr. Egbuonu-Davis brings to
our Board of Directors broad strategic and operational experience in pharmaceuticals, public health, and consulting, including expertise
in developing and implementing research, commercialization, and investment strategies for a variety of patient populations. Since 2019,
Dr. Egbuonu-Davis has served as Vice President, Medical Innovations for DH Diagnostics, LLC, an affiliate of Danaher Corporation (NYSE:
DHR), where she provides medical advice to influence research, partnership, and investment strategy across Danaher’s diagnostic
platform businesses. From 2015 to 2019, she served as Vice President, Global Patient Centered Outcomes and Solutions at Sanofi, Inc. (NASDAQ:
SNY). At Sanofi, Dr. Egbuonu-Davis created patient programs, services and tools to enhance adherence and health outcomes in patients with
chronic conditions. Prior to Sanofi, Dr. Egbuonu-Davis co-founded and served as director for ROI Squared, LLC, a privately-held life science
company focused on diagnostic medical devices, and served as managing director for LED Enterprise, LLC, where she advised biopharmaceutical
companies and trade associations on health care reform, technology assessment, quality metrics and incentives and implications for research
and services. She also served in senior advisor roles for Avalere Health and Booz Allen Hamilton. She also previously served for 13 years
in various roles at Pfizer, Inc. (NYSE: PFE), where she led clinical and outcomes research departments, supported product value assessments
in support of reimbursement and adoption and influenced product investment and development decisions. Dr. Egbuonu-Davis currently serves
on the Johns Hopkins Medicine Board of Trustees and the National Advisory Council for the Johns Hopkins University School of Education.
She earned her Master of Business Administration in Health Care Management from The Wharton School of the University of Pennsylvania,
and she holds Doctor of Medicine and Master of Public Health (epidemiology) degrees from Johns Hopkins University.
There are no family relationships
between Dr. Egbuonu-Davis and any director or other executive officer of the Company nor are there any transactions between Dr. Egbuonu-Davis
or any immediate family member and the Company or any of its subsidiaries that would be reportable as a related party transaction under
the rules of the United States Securities and Exchange Commission. Further, there is no arrangement or understanding between Dr. Egbuonu-Davis
and any other persons or entities pursuant to which Dr. Egbuonu-Davis was appointed as a director of the Company.
Dr.
Egbuonu-Davis will receive compensation for services as a director pursuant to the Company’s standard arrangements for non-employee
directors. For the period from the date of Dr. Egbuonu-Davis’s appointment through the 2022 Annual Meeting, the annual amounts for
non-employee director compensation will be prorated.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
OMEGA HEALTHCARE INVESTORS, INC.
|
|
|
|
Dated: August 2, 2021
|
By:
|
/s/ Gail D. Makode
|
|
|
Gail D. Makode
|
|
|
Chief Legal Officer, General Counsel
|
Omega Healthcare Investors (NYSE:OHI)
Historical Stock Chart
From Apr 2024 to May 2024
Omega Healthcare Investors (NYSE:OHI)
Historical Stock Chart
From May 2023 to May 2024